Sign In
Buy SNY
$44.38
+2.01 (+4.74%)
At Close: Jun 04, 2026
SNY Stock Alert: Why 1 Analyst Says Zantac Ruling Is ‘Best-Case Scenario' for Drugmakers
11:27am, Wednesday, 07'th Dec 2022
Sanofi (NASDAQ: SNY ) stock is in the news as one analyst believes the latest court ruling is the “best-case scenario” for the drugmaker. The big news here is U.S. District Judge Robin Rosenberg d
GSK and Sanofi shares surge after Florida ruling dismisses Zantac lawsuits in what one analyst describes as ‘best-case scenario'
06:06am, Wednesday, 07'th Dec 2022
Shares of pharmaceutical giants GSK PLC and Sanofi SA soared on Wednesday after what one analyst described as a “best-case scenario” Florida ruling that dismissed thousands of potential lawsuits o
GSK, Sanofi Shares Jump After U.S. Judge Dismisses Zantac Lawsuit
04:42am, Wednesday, 07'th Dec 2022
Tens of thousands of lawsuits alleged that the heartburn treatment could cause cancer. Complaints are still active in state courts.
GSK, Sanofi shares brighten as thousands of Zantac lawsuits are dismissed
04:17am, Wednesday, 07'th Dec 2022
Shares of GSK and Sanofi surged in early trading on Wednesday, following the dismissal of thousands of U.S. lawsuits claiming that the heartburn drug Zantac caused cancer.
These 3 Stocks Escaped Tuesday's Market Downdraft
05:11pm, Tuesday, 06'th Dec 2022
Even a dour outlook for the broader stock market couldn't outweigh good news for these companies.
Why GSK Plc And Sanofi SA Stock Are Shooting Higher - GSK (NYSE:GSK), Sanofi (NASDAQ:SNY)
04:20pm, Tuesday, 06'th Dec 2022
Shares of GSK plc GSK and Sanofi SA SNY are trading higher going into the close of Tuesday's session after the companies reportedly won a Zantac product liability lawsuit.
Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sanofi
09:43am, Monday, 05'th Dec 2022
Johnson & Johnson dropped out of the bidding process for Horizon Therapeutics, pushing HZNP stock into the red on Monday. The post Horizon Topples After J&J Pulls Out Of Bidding War, Leaving Amgen, Sa
Horizon Therapeutics in preliminary sale talks with Amgen, Sanofi, J&J
10:37am, Wednesday, 30'th Nov 2022
CNBC's Jim Cramer and the 'Squawk on the Street' team discuss a new report that Horizon Therapeutics is in preliminary talks with major pharmaceutical companies over a potential takeover.
Horizon Therapeutics Rockets As It Considers Potential Bids From Amgen, J&J, Sanofi
05:38pm, Tuesday, 29'th Nov 2022
Horizon said Tuesday it's considering potential offers from three Big Pharma stalwarts, sending HZNP stock soaring more than 30% after hours. The post Horizon Therapeutics Rockets As It Considers Pote
12 Potent Picks Are December's Ideal Dividend Buys
10:04am, Tuesday, 29'th Nov 2022
A February 2, 2022, Kiplinger Today special report headlined, "Potent Picks to Profit in 2022,” featured 97 dividend-fetching stocks from 118 in that article. Here is YCharts 11/25/22 update. Articl
Sanofi's (SNY) Rare Anemia Drug Enjaymo Gets EU Approval
01:41pm, Friday, 18'th Nov 2022
Sanofi's (SNY) Enjaymo gets approval to treat hemolytic anemia in adult patients with cold agglutinin disease (CAD) in Europe.
Sanofi (SNY), Regeneron Dupixent Gets CHMP Nod for Skin Disease
09:02am, Monday, 14'th Nov 2022
The CHMP recommends approval of Sanofi's (SNY) Dupixent for the treatment of prurigo nodularis, a chronic inflammatory skin disease.
Top 5 stories of the week: Meta layoffs, Sanofi's billion-dollar deal and Snowflake updates
08:00am, Saturday, 12'th Nov 2022
Meta's massive layoff announcement led our coverage this week, but on the other end of the spectrum, biotech company Sanofi announced a billion-dollar deal in AI drug discovery.
Sanofi (SNY), GSK Receive EU Approval for COVID-19 Vaccine
01:33pm, Friday, 11'th Nov 2022
Sanofi (SNY) and partner GSK's COVID-19 vaccine receives authorization in the European Union for use as a booster in adults aged 18 years and older.
Sanofi SA (SNY) Q3 2022 Earnings Call Transcript
03:40pm, Friday, 28'th Oct 2022
Sanofi SA (NASDAQ:SNY ) Q3 2022 Results Conference Call October 28, 2022 8:30 AM ET Company Participants Eva Schaefer-Jansen - Head, IR Paul Hudson - CEO Bill Sibold - EVP, Specialty Care; President,
